Your New Training Baseline on GLP-1 Most people on Ozempic or similar GLP-1 medications find their sustainable training volume is 70 to 80 percent of what it was before starting medication
Take the Assessment Free initial physician consultation Access to GLP-1 medications plus complementary peptides (BPC-157, CJC-1295/Ipamorelin, and more) Ongoing physician monitoring and protocol adjustment Transparent pricing with no hidden fees Frequently Asked Questions Which program is cheaper
It works best alongside a balanced diet with adequate protein, fiber, hydration, and movement
The compound has demonstrated generally good tolerability in clinical trials to date, with a safety profile largely consistent with other incretin-based therapies (GLP-1 and GLP-1/GIP agonists) that have become standard treatments for obesity and type 2 diabetes
Initial effects likely reflect water weight fluctuation rather than fat loss
It signals a shift toward: More patient-friendly formats Broader primary care adoption Earlier preventive intervention Increased competition in the GLP-1 space As with all GLP-1 therapies, safety and tolerability remain important considerations, and patient selection will be key
:format(webp))
